Jorge Leguizamo, MD
Hematology & Oncology · Lawrenceville, GANPI 1285612168
Payments from drug & device makers
Across 409 payments — averaging $1000.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$136K
- AbbVie$88K
- Apellis Pharmaceuticals, Inc.$76K
- Johnson & Johnson$28K
- Pharmacyclics LLC, An Abbvie Company$18K
- Novartis$16K
- plus $48K from 30 others
What the payments were for
- Consulting fees$116,43428%
- Speaking & faculty fees$251,65461%
- Travel & lodging$33,8958%
- Food & beverage$7,1352%
- Education$2780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 120 | $136,079 |
| AbbVie | 80 | $87,649 |
| Apellis Pharmaceuticals, Inc. | 49 | $76,234 |
| Johnson & Johnson | 35 | $27,790 |
| Pharmacyclics LLC, An Abbvie Company | 16 | $18,057 |
| Novartis | 15 | $16,011 |
| Sanofi | 8 | $9,536 |
| Epizyme, Inc. | 10 | $7,401 |
| GSK | 3 | $5,144 |
| Janssen Scientific Affairs, LLC | 3 | $4,803 |
| Karyopharm Therapeutics Inc. | 2 | $3,875 |
| Spectrum Pharmaceuticals Inc. | 8 | $3,228 |
| E.r. Squibb & Sons, L.L.C. | 4 | $3,178 |
| ADC Therapeutics America, Inc. | 1 | $2,400 |
| Bristol Myers Squibb | 10 | $2,000 |
| Beigene USA, Inc. | 3 | $1,916 |
| CTI Biopharma Corp. | 1 | $1,725 |
| Incyte Corporation | 3 | $1,333 |
| Exelixis Inc. | 6 | $209 |
| Pfizer | 9 | $172 |
| Ipsen Biopharmaceuticals, Inc | 2 | $109 |
| Adaptive Biotechnologies Corporation | 1 | $104 |
| Daiichi Sankyo Inc. | 4 | $88 |
| Eisai Inc. | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Tersera Therapeutics LLC | 1 | $36 |
| Array Biopharma Inc | 2 | $32 |
| Beone Medicines USA, Inc. | 1 | $31 |
| Caris MPI, Inc. | 1 | $29 |
| Bayer | 1 | $29 |
| Amgen | 1 | $28 |
| Lilly USA, LLC | 1 | $24 |
| Sobi, Inc | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$409,396 in reported general payments places this provider in the 85th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 44 | $916,024 |
| SprycelDasatinib | 14 | $242,894 |
| ImbruvicaIbrutinib | 15 | $239,585 |
| IbrancePalbociclib | 15 | $231,498 |
| CalquenceAcalabrutinib Maleate | 15 | $227,445 |
| JakafiRuxolitinib Phosphate | 12 | $207,555 |
| XtandiEnzalutamide | 13 | $184,313 |
| BrukinsaZanubrutinib | 12 | $167,954 |
| Abiraterone Acetate | 29 | $124,669 |
| EliquisApixaban | 92 | $71,293 |
| Everolimus | 12 | $21,258 |
| XareltoRivaroxaban | 21 | $19,144 |
| Morphine Sulfate ErMorphine Sulfate | 40 | $1,258 |
| Hydroxyurea | 30 | $1,187 |
| Morphine Sulfate | 12 | $801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $2,000 | $916,02444 claims |
| PfizerIbrance, Eliquis | $172 | $302,791107 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $3,178 | $242,89414 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $18,057 | $239,58515 claims |
| AstraZenecaCalquence | $136,079 | $227,44515 claims |
| Incyte CorporationJakafi | $1,333 | $207,55512 claims |
| Beigene USA, Inc.Brukinsa | $1,916 | $167,95412 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $4,803 | $124,66929 claims |
| Johnson & JohnsonXarelto | $27,790 | $19,14421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Lawrenceville
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Amelia ZelnakCumming$4.4M
- Conor SteuerAtlanta$4.4M
- Anthony HunterAtlanta$4.3M
- Robert BrownAtlanta$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.